secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNBX Pharmaceuticals Inc. (CNBX)
CIK:        0001343009
Form:       8-K
Filed at:   2022-07-25T23:59:59+00:00
Accession:  0001683168-22-005100
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CNBX appoints Dr. Sanja Goldberg as CTO, replacing Dr. Eyal Ballan
------------------------------------------------------------------

- Dr. Eyal Ballan resigned as CTO and employment ended effective July 20, 2022.
- Dr. Sanja Goldberg appointed as new CTO on July 24, 2022.
- Goldberg previously held senior researcher roles at Sheba Medical Center's Cancer Research Lab.
- She held executive positions at Compugen and TaGeza Biopharma (VP R&D).
- Goldberg earned a Ph.D. in Cell Biology from Erasmus MC, Rotterdam in 2009.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1343009/000168316822005100/0001683168-22-005100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1343009/000168316822005100/cnbx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-005100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer